Quick Comparison
| Niacinamide | Tranexamic Acid | |
|---|---|---|
| Typical Concentration | Concentrations: 2-10%. 5% is the most studied concentration and provides the best balance of efficacy and tolerability. Higher concentrations (10%) are available but may cause irritation in sensitive skin without proportional benefit. Apply morning and/or night. | Topical: 2-5% in serum or cream, applied twice daily. Oral (off-label for melasma): 250 mg twice daily — requires medical supervision. Can be combined with other brightening agents. Results visible at 8-12 weeks. Especially effective for melasma. |
| Application | Topical (serum, moisturizer, toner). Water-soluble. Stable in formulation. Compatible with most actives. | Topical (serum, cream) or oral (tablets, off-label). Topical preferred for safety. Oral is more effective but carries systemic risks. |
| Research Papers | 10 papers | 10 papers |
| Categories |
Mechanism of Action
Niacinamide
Niacinamide is converted to NAD+ via the Preiss-Handler pathway—essential for cellular respiration, DNA repair (PARP), and sirtuin regulation. In keratinocytes, it upregulates serine palmitoyltransferase and fatty acid elongases, increasing ceramide synthesis and strengthening the barrier. It inhibits melanosome transfer by downregulating protease-activated receptor-2 (PAR-2) on keratinocytes—brightening without tyrosinase inhibition. In sebocytes, it normalizes lipid synthesis and reduces sebum (possibly via AMPK). Niacinamide inhibits NF-kB translocation, suppressing IL-1beta, TNF-alpha, and IL-8. It inhibits phosphodiesterase, increasing cAMP and modulating keratinocyte differentiation. These multi-pathway effects explain broad efficacy across barrier repair, brightening, acne, and anti-aging.
Tranexamic Acid
Tranexamic acid (TXA) is a lysine analogue that competitively inhibits plasminogen activation—binding lysine-binding sites and preventing conversion to plasmin by tPA and uPA. Plasmin normally activates multiple pathways: converts latent TGF-beta to active form, stimulates keratinocyte release of arachidonic acid and prostaglandins (PGE2, PGF2-alpha), and increases SCF and bFGF—all stimulating melanocyte proliferation and melanogenesis. By blocking plasmin, TXA interrupts this paracrine cascade, reducing melanin through a mechanism independent of tyrosinase. TXA also inhibits VEGF and reduces angiogenesis—addressing melasma's vascular component. May reduce UV-induced plasmin in keratinocytes. This unique mechanism makes TXA synergistic with tyrosinase inhibitors for stubborn melasma.
Risks & Safety
Niacinamide
Common
Very well-tolerated at 2-5%. Flushing/redness at concentrations above 5% in some individuals.
Serious
None documented.
Rare
Contact dermatitis (uncommon). Old advice to avoid combining with vitamin C is largely debunked at product pH levels.
Tranexamic Acid
Rare
Topical form has minimal systemic absorption and low risk.
Full Profiles
Niacinamide →
A true multitasker — niacinamide (vitamin B3) addresses almost every skin concern simultaneously. It strengthens the skin barrier by boosting ceramide production, reduces hyperpigmentation by inhibiting melanosome transfer, controls sebum production, minimizes pore appearance, reduces redness, and has anti-aging benefits. One of the most versatile and well-tolerated actives in skincare.
Tranexamic Acid →
Originally an oral medication for heavy menstrual bleeding, tranexamic acid (TXA) has emerged as one of the most effective treatments for melasma and stubborn hyperpigmentation that does not respond to conventional treatments. It works through a unique mechanism — blocking plasmin-mediated stimulation of melanocytes — that is different from tyrosinase inhibitors, making it an excellent combination partner.